A novel structural variant of the human beta 4 integrin cDNA

Area of Science:

• Cell biology
• Integrin signaling
• Cancer research

Background:

• The alpha 6 beta 4 integrin's role as a laminin receptor is cell-type specific.
• Structural variants in the beta 4 cytoplasmic domain may regulate integrin function.
• Previous research identified a 70 amino acid insert in the beta 4 cytoplasmic domain.

Purpose of the Study:

• To investigate novel structural variants of the alpha 6 beta 4 integrin's beta 4 cytoplasmic domain.
• To determine the expression of a newly identified 7 amino acid deletion variant in the beta 4 cytoplasmic domain.
• To explore the functional implications of beta 4 cytoplasmic domain variants on alpha 6 beta 4 integrin activity.

Main Methods:

• Isolation of beta 4 clones from a colon carcinoma cell line (clone A) cDNA library.
• Polymerase Chain Reaction (PCR) analysis to detect specific beta 4 variants in RNA samples.
• Sequence analysis to identify structural variations within the beta 4 cytoplasmic domain.

Main Results:

• A novel 21 base pair (7 amino acid) in-frame deletion variant in the beta 4 cytoplasmic domain was identified.
• This 7 amino acid variant lacks the four potential serine/threonine phosphorylation sites found in a previously reported 70 amino acid insert.
• The 7 amino acid variant is expressed in RNA from normal colon and placenta, indicating its presence in both cancerous and normal tissues.

Conclusions:

• A novel variant of the alpha 6 beta 4 integrin's beta 4 cytoplasmic domain exists, characterized by a 7 amino acid deletion.
• The absence of phosphorylation sites in this variant suggests a potentially distinct regulatory mechanism compared to other beta 4 variants.
• The expression of this variant in normal colon and placenta implies its potential physiological relevance beyond cancer.